Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy

被引:1
作者
Gebreyesus, Manna Semere [1 ]
Wasmann, Roeland E. [1 ]
McIlleron, Helen [1 ]
Oladokun, Regina [2 ]
Okonkwo, Prosper [3 ]
Wiesner, Lubbe [1 ]
Denti, Paolo [1 ]
Rawizza, Holly E. [4 ,5 ]
机构
[1] Univ Cape Town, Dept Med, Div Clin Pharmacol, Cape Town, South Africa
[2] Univ Ibadan, Fac Clin Sci, Dept Pediat, Coll Med, Ibadan, Nigeria
[3] APIN Publ Hlth Initiat APIN, Abuja, Nigeria
[4] Brigham & Womens Hosp, Boston, MA USA
[5] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
关键词
pediatric; infectious diseases; drug interactions; rifabutin; antiretroviral therapy; DRUG-INTERACTION; TUBERCULOSIS; MATURATION; LOPINAVIR; PREDICT; SAFETY; MODEL;
D O I
10.1128/aac.00354-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In adults requiring protease inhibitor (PI)-based antiretroviral therapy (ART), replacing rifampicin with rifabutin is a preferred option, but there is lack of evidence to guide rifabutin dosing in children, especially with PIs. We aimed to characterize the population pharmacokinetics of rifabutin and 25-O-desacetyl rifabutin (des-rifabutin) in children and optimize its dose. We included children from three age cohorts: (i) <1-year-old cohort and (ii) 1- to 3-year-old cohort, who were ART na & iuml;ve and received 15- to 20-mg/kg/day rifabutin for 2 weeks followed by lopinavir/ritonavir (LPV/r)-based ART with 5.0- or 2.5 mg/kg/day rifabutin, respectively, while the (iii) >3-year-old cohort was ART-experienced and received 2.5-mg/kg/day rifabutin with LPV/r-based ART. Non-linear mixed-effects modeling was used to interpret the data. Monte Carlo simulations were performed to evaluate the study doses and optimize dosing using harmonized weight bands. Twenty-eight children were included, with a median age of 10 (range 0.67-15.0) years, a median weight of 11 (range 4.5-45) kg, and a median weight-for-age z score of -3.33 (range -5.15 to -1.32). A two-compartment disposition model, scaled allometrically by weight, was developed for rifabutin and des-rifabutin. LPV/r increased rifabutin bioavailability by 158% (95% confidence interval: 93.2%-246.0%) and reduced des-rifabutin clearance by 76.6% (74.4%-78.3%). Severely underweight children showed 26% (17.9%-33.7%) lower bioavailability. Compared to adult exposures, simulations resulted in higher median steady-state rifabutin and des-rifabutin exposures in 6-20 kg during tuberculosis-only treatment with 20 mg/kg/day. During LPV/r co-treatment, the 2.5-mg/kg/day dose achieved similar exposures to adults, while the 5-mg/kg/day dose resulted in higher exposures in children >7 kg. All study doses maintained a median C-max of <900 <mu>g/L. The suggested weight-band dosing matches adult exposures consistently across weights and simplifies dosing.
引用
收藏
页数:15
相关论文
共 42 条
[1]   Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update [J].
Alsultan, Abdullah ;
Peloquin, Charles A. .
DRUGS, 2014, 74 (08) :839-854
[2]   A maturation model for midazolam clearance [J].
Anderson, Brian J. ;
Larsson, Peter .
PEDIATRIC ANESTHESIA, 2011, 21 (03) :302-308
[3]   Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans [J].
Anderson, Brian J. ;
Holford, Nick H. G. .
DRUG METABOLISM AND PHARMACOKINETICS, 2009, 24 (01) :25-36
[4]  
[Anonymous], 2011, Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents
[5]   Paediatric pharmacokinetics: key considerations [J].
Batchelor, Hannah Katharine ;
Marriott, John Francis .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (03) :395-404
[6]   Ways to fit a PK model with some data below the quantification limit [J].
Beal, SL .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (05) :481-504
[7]  
Beal SL., 2008, NONMEM USERS GUIDE P
[8]   Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models [J].
Bergstrand, Martin ;
Hooker, Andrew C. ;
Wallin, Johan E. ;
Karlsson, Mats O. .
AAPS JOURNAL, 2011, 13 (02) :143-151
[9]   Pharmacokinetic Evaluation of Rifabutin in Combination with Lopinavir-Ritonavir in Patients with HIV Infection and Active Tuberculosis [J].
Boulanger, Catherine ;
Hollender, Elena ;
Farrell, Karen ;
Stambaugh, Jerry Jean ;
Maasen, Diane ;
Ashkin, David ;
Symes, Stephen ;
Espinoza, Luis A. ;
Rivero, Rafael O. ;
Graham, Jenny J. ;
Peloquin, Charles A. .
CLINICAL INFECTIOUS DISEASES, 2009, 49 (09) :1305-1311
[10]  
Clinton Health Acess Initiative (CHAI), 2023, HIV MARKET REPORT IN